BG Medicine Q3 Revenues Spike as Restructuring Aims to Ramp up Commercialization | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine said today that revenues in the third quarter rose 258 percent year over year on the sale of it BGM Galectin-3 test.

Separately, the Waltham, Mass.-based firm also announced a commercialization strategy intended to accelerate adoption of its cardiovascular diagnostics tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.